Glucose energy conversion is mainly through oxidative phosphorylation, glycolysis, and pentose phosphate pathways. Research in the field of tumor metabolism can be roughly divided into three major metabolic regulations in tumors, reprogramming, epigenetic modification of metabolites, changes in metabolism-related signaling pathways, and interactions between metabolic regulatory genes and oncogenes. It has been confirmed that several genes can regulate tumor metabolism, including genes that regulate tumor glucose metabolism, oncogenes, and tumor suppressors. The study of glucose metabolism-related genes to regulate the reprogramming of glucose metabolism and the correction of abnormal cell metabolism has become a new idea for preventing the occurrence and development of tumors and treating tumors. CD BioGlyco can provide gene-level regulatory analysis of cancer glucose metabolism.
Gene mutation has become an important factor in tumorigenesis, and the mutual regulation of cellular glucose metabolism and gene expression is characteristic of tumor cells. Although cancer cell metabolism is regulated by glucose metabolic enzymes in metabolic pathways, glucose metabolic enzymes are directly regulated by metabolism-related genes.
Our MOPCGM platform enables the study of the link between oncogenes, tumor suppressors and glucose metabolism, non-coding RNAs, epigenetics, and other mechanisms of glucose metabolism regulation. The above information provides new ideas for researchers in the field of biological sciences, pharmaceutical R&D companies, etc. to prevent the occurrence and development of tumors and treat tumors by targeting the glucose metabolism process of cancer cells and correcting abnormal cell metabolism.
Oncogenes are usually highly expressed in various cancers, and regulate the transcription of various glycolysis-related genes to regulate the glucose metabolism of cancer cells. We are able to provide an analysis of oncogenes regulating glucose metabolism in cancer cells.
Tumor suppressors are usually mutated in tumors and inhibit the glucose metabolism of cancer cells by regulating mitochondrial respiration, pentose phosphate pathway, glycolysis-related enzymes, etc. We are able to provide an analysis of the molecular mechanisms by which tumor suppressors regulate cancer glucose metabolism.
Non-coding RNA includes microRNA, long non-coding RNA, etc. Non-coding RNAs can participate in the transcription, silencing, activation, and other processes of glucose metabolism-related genes to regulate metabolic reprogramming. We are able to provide an analysis of the molecular mechanisms by which non-coding RNAs regulate cancer glucose metabolism.
Epigenetic modification mainly regulates the energy supply and expression level of glucose metabolism-related genes through DNA methylation, histone modification, non-coding RNA regulation, and chromatin structural remodeling, and regulates the reprogramming of glucose metabolism in cancer cells. We are able to provide an analysis of the role epigenetic modifications play in the reprogramming of glucose metabolism in cancer cells.
Our services can support the following applications, including but not limited to:
CD BioGlyco can provide gene-level analysis of the reprogramming of cancer glucose metabolism, which is mainly divided into the analysis of the roles of oncogenes, tumor suppressors, non-coding RNAs and epigenetic modifications in the regulation of cancer glucose metabolism. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.